The Science Behind Your Wegovy 1.7mg vs Mounjaro Decision
Wegovy 1.7mg vs Mounjaro: Mechanism Comparison
Wegovy 1.7mg delivers semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors—a dual incretin approach. Both prescription-only medicines work on brain appetite centres to reduce food cravings and promote satiety after smaller meals. The choice between single-pathway (Wegovy) and dual-pathway (Mounjaro) depends on your individual response and medical profile.
At the Wegovy 1.7mg stage, you're experiencing the medication's near-maximum effect before reaching 2.4mg maintenance. Mounjaro's equivalent phase occurs around 10-12.5mg, with both treatments requiring careful dose escalation. Your prescriber can assess which mechanism suits your physiology, considering factors like diabetes status, cardiovascular health, and previous treatment responses. The dual-pathway approach isn't necessarily superior—individual variation in receptor sensitivity determines effectiveness.
Wegovy 1.7mg Pricing vs Mounjaro Cost Analysis
Wegovy 1.7mg costs £139.99 through EverydayMeds, positioning it competitively against equivalent Mounjaro doses. Our Elevate Duo bundle (1.7mg plus 2.4mg maintenance) provides seamless transition planning for £369.99. Returning customers apply code DOSE25 at checkout to maintain optimal pricing throughout their treatment journey. This weeks 13-16 dose represents significant value as you approach peak effectiveness.
Mounjaro's pricing varies by dose strength, with equivalent effectiveness stages often differing in cost structure. Both treatments qualify for the same clinical assessment process through our GPhC #9012878 registered pharmacy. Bundle options exist for both medications, allowing you to secure supply continuity. The Elevate Duo specifically addresses the Wegovy 1.7mg user's next step—transitioning to maintenance without supply interruption.
Clinical Evidence: Wegovy 1.7mg Performance vs Mounjaro Trials
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 study (Wilding et al., NEJM, 2021). The 1.7mg dose represents week 13-16 of this escalation protocol, where therapeutic effects typically accelerate. Mounjaro trials used different methodologies, making direct percentage comparisons inappropriate.
Both medications demonstrated cardiovascular benefits in their respective trials, with Wegovy's SELECT study showing 20% reduction in major cardiovascular events. The Wegovy 1.7mg dose sits within the therapeutic range where these benefits manifest. Individual responses vary significantly, and your prescriber can assess which evidence base aligns better with your health profile and treatment goals.
How Wegovy 1.7mg Works in Your System
Wegovy 1.7mg functions as a GLP-1 receptor agonist, binding to receptors in your brain's appetite control centres. This binding triggers cascade effects that reduce hunger signals and enhance satiety responses after eating. The once-weekly injection maintains therapeutic levels throughout seven days, providing consistent appetite modulation. Unlike oral medications, the subcutaneous delivery ensures reliable absorption regardless of food intake or digestive variations. At the 1.7mg strength, you're experiencing near-optimal receptor activation before reaching the 2.4mg maintenance dose, designed to work alongside a reduced-calorie diet and increased physical activity.
Ordering Your Wegovy 1.7mg vs Mounjaro Assessment
EverydayMeds streamlines access to both treatments through a comprehensive 3-minute online clinical assessment. Our prescribers review your medical history, current medications, and treatment goals within 3 working days (express 24-hour service available). The assessment considers your specific needs at the Wegovy 1.7mg stage versus starting Mounjaro's escalation protocol. Once approved, next-day delivery ensures cold-chain integrity from our GPhC-registered facility. Both medications require prescription-only oversight, with ongoing monitoring throughout your treatment journey ensuring optimal safety and effectiveness.
Storage Advantages: Wegovy 1.7mg vs Mounjaro Practicality
Wegovy 1.7mg offers superior storage flexibility, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration. Mounjaro requires return to refrigeration within 21 days, potentially limiting travel and lifestyle flexibility. Both use pre-filled pen devices, but Wegovy's FlexTouch pen design may suit different dexterity requirements. Standard storage requires 2-8°C refrigeration before first use, with both medications maintaining potency throughout their shelf life. This storage advantage becomes particularly relevant for users maintaining long-term treatment or frequent travellers requiring portable medication management.
Wegovy 1.7mg Stage vs Mounjaro Equivalent Timing
Your Wegovy 1.7mg dose represents weeks 13-16 of the escalation protocol—a crucial period where therapeutic effects typically peak before maintenance. Mounjaro's equivalent therapeutic window occurs later in its 6-dose escalation, around the 10-12.5mg range. This timing difference affects treatment planning, especially for users switching between medications. EverydayMeds clinical team coordinates such transitions, ensuring appropriate washout periods and dose adjustments.
The Wegovy 1.7mg stage often coincides with plateau-breaking moments, where initial adaptation gives way to renewed progress. Mounjaro users may experience different timing of peak effects due to its dual-receptor mechanism. Your prescriber can assess whether continuing Wegovy 1.7mg progression or switching to Mounjaro's protocol better serves your individual response pattern and long-term treatment objectives.
Making Your Wegovy 1.7mg vs Mounjaro Decision
Both treatments remain available through EverydayMeds, eliminating supply chain concerns regardless of your choice. Your prescriber evaluates factors including diabetes status, previous GLP-1 experience, injection frequency preferences, and storage requirements. The Wegovy 1.7mg dose offers predictable progression toward 2.4mg maintenance, while Mounjaro provides alternative mechanism targeting. Consider booking your clinical assessment to discuss both options with our qualified prescribers, using code DOSE25 for returning customers or FIRST40 for new consultations. Our GPhC #9012878 registered pharmacy ensures consistent supply of whichever treatment proves optimal for your individual circumstances and treatment goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
